huCD7/huCD20 Mouse
製品名
huCD7/huCD20 Mouse
製品ID
C002128
系統名
C57BL/6Cya-Cd7tm1(hCD7)Ms4a1em1(hMS4A1)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「huCD7/huCD20 Mouse（カタログ番号C002128）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子別名
GP40, TP41, Tp40, LEU-9, B1, S7, Bp35, CD20, FMC7, CVID5, LEU-16
染色体
Chr 17, Chr 11
さらに
系統詳細
The CD7 gene encodes a transmembrane glycoprotein in the immunoglobulin superfamily (IgSF). As an important co-receptor on the T cell surface, it plays a key regulatory role in T cell activation, proliferation, and signal transduction. CD7 is mainly expressed in T cells and natural killer (NK) cells, from early thymocyte development to the mature T cell stage, and also in some hematopoietic progenitor cells; however, its expression level is low in most normal non-T cell and NK cell tissues [1]. Abnormal expression or dysregulated signaling of CD7 is closely related to multiple diseases. As an important target for immunotherapy, CD7 has become a key molecule for targeting T-cell malignancies due to its high expression in T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoma, and other T-cell malignant tumors [1]. In addition, CD7 is also associated with systemic sclerosis (SSc) and graft-versus-host disease (GvHD) [2-3].
Cluster of differentiation 20 (CD20), also known as MS4A1, is a functional receptor molecule on the surface of B lymphocytes, closely related to B cell activation, signal transduction, and growth regulation. CD20 is expressed at the late stage of B-cell lymphopoiesis and disappears after differentiation into plasma cells. Therefore, CD20 is expressed from pre-B cells to mature B cells, but not in plasma cells [4].
The huCD7/huCD20 mouse is a dual-gene humanized model obtained by crossing the huCD7 mouse (Catalog No.: C002067) with the huCD20 mouse (Catalog No.: C001625). This model can be used for studying the immune mechanisms of CD7/CD20-related malignant tumors, as well as for screening, efficacy evaluation, and safety assessment of CD7/CD20-targeted drugs.
参考文献
Freiwan A, Zoine JT, Crawford JC, et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022;140(25):2684-2696.
Papadimitriou Theodoros Ioannis, Singh Prashant, et al.CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for selective cell depletion. Ann Rheum Dis. 2024;83(4):488-498.
Tingting Yang, et al. Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies. Blood. 2025;146(1):1040.
Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994 Sep;15(9):450-4.
系統作製戦略
The huCD7/huCD20 mouse is a dual-gene humanized model obtained by crossing the huCD7 mouse (Catalog No.: C002067) with the huCD20 mouse (Catalog No.: C001625).
Figure 1. Gene editing strategy of huCD7 mice. The mouse Cd7 endogenous signal peptide and extracellular domain were replaced with the human CD7 signal peptide and extracellular domain. The expression of mouse Gm11775 would be affected by this KI region.
Figure 2. Gene editing strategy of huCD20(MS4A1) mice. The sequence from the ATG start codon to the TAA stop codon of the endogenous mouse Ms4a1 gene was replaced with the sequence from the ATG start codon to the TAA stop codon of the human MS4A1 gene.
適用分野
Research on the immune mechanisms of CD7/CD20-associated malignancies;
Screening, efficacy evaluation, and safety assessment of CD7/CD20-targeted drugs.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。